Qianhai Health Holdings Limited (0911.HK)
HKD 0.21
(0.0%)
HKD 0.21
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -19.03 Million HKD | -4084.18% |
| 2022 | -455 Thousand HKD | -108.49% |
| 2021 | 5.36 Million HKD | -30.38% |
| 2020 | 7.7 Million HKD | -86.36% |
| 2019 | 56.46 Million HKD | 140.87% |
| 2018 | -138.14 Million HKD | 17.85% |
| 2017 | -168.17 Million HKD | 31.13% |
| 2016 | -244.18 Million HKD | -116.39% |
| 2015 | 1.48 Billion HKD | -1.66% |
| 2014 | 1.51 Billion HKD | 375.62% |
| 2013 | 318.45 Million HKD | 2335.52% |
| 2012 | -14.24 Million HKD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.38 Million HKD | 87.46% |
| 2024 Q2 | -2.26 Million HKD | 5.15% |
| 2023 Q3 | -19.52 Million HKD | -134.56% |
| 2023 Q1 | -9.04 Million HKD | -1887.25% |
| 2023 FY | -19.03 Million HKD | -4084.18% |
| 2023 Q2 | -8.32 Million HKD | 7.94% |
| 2023 Q4 | -19.03 Million HKD | 2.49% |
| 2022 FY | -455 Thousand HKD | -108.49% |
| 2022 Q4 | -455 Thousand HKD | 60.61% |
| 2022 Q3 | -1.15 Million HKD | 99.29% |
| 2022 Q2 | -163.12 Million HKD | 0.19% |
| 2022 Q1 | -163.42 Million HKD | -3148.46% |
| 2021 FY | 5.36 Million HKD | -30.38% |
| 2021 Q4 | 5.36 Million HKD | 14.19% |
| 2021 Q2 | 12.82 Million HKD | 5.87% |
| 2021 Q3 | 4.69 Million HKD | -63.39% |
| 2021 Q1 | 12.11 Million HKD | 57.31% |
| 2020 Q3 | 7 Million HKD | -34.72% |
| 2020 FY | 7.7 Million HKD | -86.36% |
| 2020 Q2 | 10.73 Million HKD | 9.6% |
| 2020 Q1 | 9.79 Million HKD | -82.66% |
| 2020 Q4 | 7.7 Million HKD | 9.91% |
| 2019 FY | 56.46 Million HKD | 140.87% |
| 2019 Q4 | 56.46 Million HKD | 1.74% |
| 2019 Q3 | 55.49 Million HKD | 144.5% |
| 2019 Q1 | -127.24 Million HKD | 7.89% |
| 2019 Q2 | -124.72 Million HKD | 1.98% |
| 2018 Q1 | -172.11 Million HKD | -2.34% |
| 2018 FY | -138.14 Million HKD | 17.85% |
| 2018 Q4 | -138.14 Million HKD | 0.07% |
| 2018 Q3 | -138.23 Million HKD | 19.64% |
| 2018 Q2 | -172.02 Million HKD | 0.05% |
| 2017 Q1 | -199.86 Million HKD | 18.15% |
| 2017 Q2 | -199.77 Million HKD | 0.05% |
| 2017 FY | -168.17 Million HKD | 31.13% |
| 2017 Q3 | -168.26 Million HKD | 15.77% |
| 2017 Q4 | -168.17 Million HKD | 0.05% |
| 2016 FY | -244.18 Million HKD | -116.39% |
| 2016 Q4 | -244.18 Million HKD | 0.04% |
| 2016 Q3 | -244.27 Million HKD | -168.23% |
| 2016 Q2 | 358.03 Million HKD | 0.11% |
| 2016 Q1 | 357.64 Million HKD | -75.99% |
| 2015 Q3 | 1.48 Billion HKD | -5.3% |
| 2015 Q2 | 1.57 Billion HKD | 0.03% |
| 2015 Q1 | 1.57 Billion HKD | 3.8% |
| 2015 FY | 1.48 Billion HKD | -1.66% |
| 2015 Q4 | 1.48 Billion HKD | 0.01% |
| 2014 Q2 | -625.58 Million HKD | 0.19% |
| 2014 Q1 | -626.74 Million HKD | -296.81% |
| 2014 Q3 | 1.51 Billion HKD | 341.94% |
| 2014 Q4 | 1.51 Billion HKD | 0.07% |
| 2014 FY | 1.51 Billion HKD | 375.62% |
| 2013 Q4 | 318.45 Million HKD | 0.42% |
| 2013 FY | 318.45 Million HKD | 2335.52% |
| 2013 Q1 | 14.24 Million HKD | 0.0% |
| 2013 Q3 | 317.11 Million HKD | 0.0% |
| 2012 FY | -14.24 Million HKD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 92.641% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 100.937% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | 420.289% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 106.314% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | 161.516% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 91.316% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 107.432% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 105.043% |
| SSY Group Limited | 1.71 Billion HKD | 101.111% |
| JBM (Healthcare) Limited | -7.39 Million HKD | -157.305% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 105.642% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 100.037% |